

**eTable 1. CAR T cells therapies in patient with and without ICANS<sup>¥</sup>**

	<b>Total (N=38)</b>	<b>Patients without ICANS (N=21)</b>	<b>Patients with ICANS (N=17)</b>	<b>P value</b>
<b>CD19-CAR constructs</b>				0.1
<b>Coreceptor CD28</b>	26 (68%)	12 (57%)	14 (82%)	
<b>Coreceptor 4-1BB</b>	12 (32%)	9 (43%)	3 (18%)	
<b>AXICABTAGENE CILOLEUCEL (CD28)</b>	21 (55%)	9 (43%)	12 (71%)	0.3
<b>BREXUCABTAGENE AUTOLEUCEL (CD28)</b>	5 (13%)	3 (14%)	2 (12%)	
<b>LISOCABTAGENE MARALEUCEL (4-1BB)</b>	7 (18%)	6 (29%)	1 (5.9%)	
<b>TISAGENLECLEUCEL (4-1BB)</b>	5 (13%)	3 (14%)	2 (12%)	

¥ ICANS: Immune effector cell-associated neurotoxicity syndrome